Upadacitinib for ulcerative colitis
- PMID: 35644164
- DOI: 10.1016/S0140-6736(22)00778-4
Upadacitinib for ulcerative colitis
Conflict of interest statement
I have received consulting fees from Ikena Oncology and Menten AI, and honorarium for lectures from Pfizer, all outside of the area of work commented on here.
Comment on
-
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26. Lancet. 2022. PMID: 35644166 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
